Essex Investment Management CO LLC Sage Therapeutics, Inc. Transaction History

Essex Investment Management CO LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $827,634 - $1.21 Million	20,360 New	20,360 $957,000
Q3 2019 Oct 22, 2019	SELL	$140.29 - $189.96 $888,316 - $1.2 Million	-6,332 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$157.85 - $183.09 $999,506 - $1.16 Million	6,332 New	6,332 $1.16 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $889,816 - $1.63 Million	-9,961 Closed	0 $0
Q4 2018 Feb 06, 2019	BUY	$81.94 - $139.71 $517,778 - $882,827	6,319 Added 173.5%	9,961 $954,000
Q3 2018 Oct 16, 2018	SELL	$138.11 - $169.04 $201,640 - $246,798	-1,460 Reduced 28.62%	3,642 $514,000
Q2 2018 Jul 17, 2018	BUY	$140.36 - $175.76 $24,282 - $30,406	173 Added 3.51%	5,102 $799,000
Q1 2018 Apr 26, 2018	SELL	$152.15 - $192.33 $228,529 - $288,879	-1,502 Reduced 23.36%	4,929 $794,000
Q4 2017 Feb 05, 2018	SELL	$60.72 - $167.34 $23,984 - $66,099	-395 Reduced 5.79%	6,431 $1.06 Million
Q3 2017 Oct 30, 2017	BUY	$61.4 - $88.52 $419,116 - $604,237	6,826	6,826 $425,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Essex Investment Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Essex Investment Management CO LLC with notifications on news.